

Beatrice Rotich et al.

Seasonal malaria chemoprevention, Kenya

This online first version has been peer-reviewed, accepted and edited,
but not formatted and finalized with corrections from authors and proofreaders

Seasonal malaria chemoprevention effectiveness and drug resistance in *Plasmodium falciparum*: a matched parallel cohort study, Kenya

Beatrice Rotich,^a Emmah Kimachas,^a Joseph Kipkoech,^a Erastus Kirwa,^a Christine Markwalter,^b David Ekai,^c Ann Mwangi,^d Suzanne Van Hulle,^e Diana Menya^f & Wendy Prudhomme O'Meara^b

^a Academic Model Providing Access to Healthcare, Eldoret, Kenya.

^b Duke Global Health Institute, 310 Trent Dr, Durham, North Carolina, NC 27710, United States of America.

^c Turkana County Government, Turkana, Kenya.

^d School of Medicine, Moi University College of Health Sciences, Eldoret, Kenya.

^e Catholic Relief Services, Geneva, Switzerland.

^f School of Public Health, Moi University College of Health Sciences, Eldoret, Kenya.

Correspondence to Wendy Prudhomme O'Meara (email: wpo@duke.edu).

(Submitted: 9 September 2025 – Revised version received: 7 April 2026 – Accepted: 24 June 2026 – Published online: 1 September 2026)

Abstract

Objective To evaluate seasonal malaria chemoprevention with sulfadoxine–pyrimethamine and amodiaquine in a semi-nomadic community in north-western Kenya, and to examine the relationship between parasite resistance and breakthrough infections.

Methods A parallel cohort study conducted during the peak malaria season in 2024 involved 10 randomly selected villages in Turkana Central subcounty, where children younger than 5 years received seasonal malaria chemoprevention, and 10 matched villages in Turkana North subcounty (non-intervention cohort). We conducted surveillance of malaria symptoms weekly. The primary outcome was malaria-like symptoms plus a positive rapid diagnostic test result. We analysed *Plasmodium falciparum* genomic DNA in dried blood spot samples from children with symptomatic infections to identify *pf dhfr* and *pf dhps* gene substitutions associated with sulfadoxine–pyrimethamine resistance.

Findings Children (198 in the intervention cohort and 200 in the non-intervention cohort) were followed until four weeks after the last chemoprevention cycle. In the intervention cohort, 72% (143/198) completed all five cycles. The incidence of malaria was significantly lower in the intervention than non-intervention cohort (adjusted incidence rate ratio 0.29; 95% confidence interval: 0.13–0.67). *Plasmodium falciparum* genomic DNA analysis of samples from 68 infected children showed that *pf dhps* gene mutations were more common in the intervention than non-intervention cohort and became more frequent as the number of treatment cycles increased.

Conclusion Seasonal malaria chemoprevention with sulfadoxine–pyrimethamine and amodiaquine was associated with substantial protection against malaria in children in an area where sulfadoxine–pyrimethamine resistance was common. Treated children were more likely to harbour resistant parasites.

Introduction

Seasonal malaria chemoprevention has been used in the Sahel region of Africa for more than a decade to reduce morbidity and mortality in vulnerable populations. In practice, antimalarials are administered to children to protect against the disease. The most commonly used regimen is a sulfadoxine–pyrimethamine combination with amodiaquine, which is administered at 28-day intervals throughout the high period for malaria transmission, usually for 3 to 5 months. Treatment clears existing infections and the long half-lives of sulfadoxine, pyrimethamine and the primary metabolite of amodiaquine, desethylamodiaquine, ensure there is prolonged protection against new infections.^{1,2} Randomized trials and large-scale implementation studies have demonstrated that seasonal malaria chemoprevention with this combination is highly effective, safe and cost-effective for preventing the disease among children in areas with seasonal malaria transmission.^{3–6}

After the World Health Organization updated guidelines on scaling up seasonal malaria chemoprevention beyond the Sahel region in 2022,⁷ countries in East Africa began exploring the integration of seasonal malaria chemoprevention into their prevention arsenal by targeting areas with highly seasonal transmission. However, parasites in this part of Africa have higher levels of sulfadoxine–pyrimethamine resistance than those in West Africa.^{8,9} In Kenya, for example, studies have documented the persistence of antifolate resistance, which reduces the parasite's susceptibility to sulfadoxine–pyrimethamine, despite withdrawal of the combination in the mid-2000s.^{8,10} Still, there is evidence supporting the continued use of sulfadoxine–pyrimethamine, for example during pregnancy, to prevent malaria in areas with moderate levels of antifolate resistance.^{7,11,12} In 2025, a seasonal malaria chemoprevention pilot study in Uganda, where antifolate resistance is high, demonstrated a 90% reduction in malaria cases.¹³ However, the relationship between antifolate resistance and the efficacy of chemoprevention with sulfadoxine–pyrimethamine and amodiaquine is not well understood.

Here we report the findings of the first seasonal malaria chemoprevention programme in an area of Kenya where communities are highly mobile, sleep out in the open and have little access to formal health services, resulting in limited conventional malaria case management and vector control. We used active case detection to determine the incidence of malaria in parallel cohorts of children in intervention and non-intervention communities and

to assess the degree of protection associated with seasonal malaria chemoprevention involving the routine administration of sulfadoxine–pyrimethamine and amodiaquine. In addition, to investigate the relationships between the effectiveness of seasonal malaria chemoprevention, breakthrough infections and parasite resistance, we tested for the presence of genetic mutations associated with antifolate resistance in samples of parasites obtained during incident infections in both cohorts.

Methods

The study took place in Turkana County in the north-western corner of Kenya, bordering Uganda to the west and Ethiopia and South Sudan to the north. Most areas have limited access to basic infrastructure, such as roads, health facilities and clean water.¹⁴ The 2019 census reported that 14% of residents were younger than 5 years.¹⁵ Annually, the mean temperature ranges between 26 and 38 °C and rainfall varies between 120 and 500 mm and is erratic in distribution and timing. Many local families are semi-nomadic and move with their herds of animals in search of pasture because little rain falls each year. Malaria outbreaks are frequent,^{16,17} with approximately 80% of cases occurring within a span of 5 months and around 30% occurring in children younger than 5 years.

Seasonal malaria chemoprevention was implemented in Turkana Central subcounty during the high transmission season in 2024 by Turkana County's health ministry with support from the Catholic Relief Services. Treatment was administered in five cycles at 28-day intervals from June to October 2024. The programme targeted children aged 3 to 59 months and more than 40 000 received at least one cycle of chemoprevention.

Study design

We conducted a prospective, partially randomized, matched, parallel-cohort study to investigate the association between seasonal malaria chemoprevention and the incidence of malaria. Although our intervention was not randomized, study villages were selected randomly to be as representative as possible. In the intervention area (i.e. Turkana Central subcounty), two villages were selected from each of the five wards containing a total of 644 villages (Fig. 1). Within each ward, villages were selected randomly, using samplepps in Stata (Stata, College Station, United States of America) with the probability that a village would be selected proportional to its size. In the non-intervention comparison area (i.e. neighbouring Turkana North subcounty), 10 villages were randomly selected from a total of 47 villages in areas served by four health facilities where malaria test positivity rates were

similar to those at facilities serving the selected Turkana Central villages. Subsequently, 20 households were randomly selected in each village by systematic random sampling from complete lists of households.

A child was eligible for inclusion in the study if they were aged between 6 and 59 months and would not pass their fifth birthday by the start of seasonal malaria chemoprevention in mid-June 2024. If more than one child was eligible in a household, auto-populated, randomized allocation was used for selection. In villages with fewer than 20 households with eligible children, we enrolled additional children from a subset of households.

A sample size of 200 children across 10 clusters in each cohort was sufficient to have 85% power at a 5% level of significance to detect a 50% difference in the proportion of children who had at least one malaria episode. We based our sample size on one episode per child because we lacked prior information about the distribution and likely overdispersion of episodes. This gave us a conservative estimate of the sample size for the desired power and significance. We estimated that 40% of children in the intervention area would have malaria during the 5-month follow-up period.

Outcome measures

The primary outcome was a positive diagnostic test result for malaria from any source accompanied by malaria-like symptoms, specifically fever, a history of fever, aches, chills and lethargy. The comparison of interest was the incidence of malaria in the cohort receiving seasonal malaria chemoprevention compared to the non-intervention cohort. A secondary outcome was the incidence of any malaria-like illness regardless of whether a test had been performed.

Illnesses were documented through active and passive surveillance. A community health promoter (also known as a community health worker or community health volunteer) visited each household in both intervention and non-intervention areas approximately once per week to ask about fever and illness. When an enrolled child was unwell, the community health promoter offered them a malaria rapid diagnostic test. The community health promoter referred children with a positive test result for treatment at the local health facility, where they received artemether–lumefantrine combination therapy free of charge. In addition, study staff members and community health promoters encouraged households to contact a community health promoter whenever a child had symptoms of malaria to receive a free test.

The community health promoters prepared a dried blood spot sample each time they performed a rapid diagnostic test. If a child was unwell and had been taken to a health facility without the community health promoter being contacted, the promoter documented the episode at the next weekly visit. The primary outcome measure included only illnesses accompanied by a positive diagnostic test result. Children were excluded from malaria testing for two weeks following a positive rapid diagnostic test result or malaria treatment to reduce the occurrence of false-positive diagnoses due to circulating antigenaemia. Community health promoters also documented instances when children travelled away from villages.

Data collection and analysis

At enrolment, we captured household and child data on an electronic form using a REDCap database (Vanderbilt University, Nashville, USA). In addition, community health promoters completed a paper questionnaire on each routine visit and we entered the data collected into the database. Twenty-eight days after the final seasonal malaria chemoprevention cycle, we recorded in each child's participation in the chemoprevention programme a final survey. We confirmed details by reviewing government-issued seasonal malaria chemoprevention cards, when available.

We conducted an intention-to-treat analysis. The incidence rate ratio of malaria episodes in the intervention group versus the non-intervention group was estimated using a mixed-effects Poisson regression model based on the number of malaria episodes per child. The model was adjusted for prespecified covariates: (i) the sex and age of the child; (ii) mosquito net ownership; (iii) whether the child slept outside; and (iv) the village-level prevalence of malaria infection at baseline. Data were analysed using Stata v. 18 (StataCorp LLC, College Station, USA) and Rstudio v. 2025.05.0+496 (Posit, Boston, USA) with R v. 4.3.1 (The R Foundation, Vienna, Austria), with the following packages: tidyverse v. 2.0.0,¹⁸ lme4 v. 1.1–34,¹⁹ survival v. 3.8–3,²⁰ survminer v. 0.5.0,²¹ broom v. 1.0.7,²² and kableExtra v. 1.4.0²³

Laboratory analysis

Dried blood spot samples were prepared from 5 to 10 µL of capillary blood obtained using a finger prick and then adsorbed onto filter paper. We tested samples collected at baseline and on active case detection for the presence of *Plasmodium falciparum* genomic DNA using a nested polymerase chain reaction (PCR) assay, starting with a Phusion Blood Direct PCR Kit (ThermoFisher Scientific, Waltham, USA) with Plu1/5 primers.²⁴ A second round of

amplification involved previously described primers,²⁵ as follows: (i) 1 µL of the primary reaction as template and 0.25 µM of forward and reverse primers; (ii) 0.3 µM probe; and (iii) 1 × SsoAdvanced Universal Probes Supermix (Bio-Rad, Hercules, USA).

When present, we extracted fresh *P. falciparum* genomic DNA from dried blood spot samples using a 5-mm punch and a Chelex-based protocol.²⁶ In addition, samples underwent testing for genetic markers of resistance to sulfadoxine–pyrimethamine using a PCR allelic discrimination assay.²⁷ There are five dominant mutations in the *P. falciparum dhfr* and *dhps* genes that have been shown to correspond to antifolate resistance in East Africa: (i) *pf dhps* A437G; (ii) *pf dhps* K540E; (iii) *pf dhfr* N51I; (iv) *pf dhfr* C59R; and (v) *pf dhfr* S108N. Substitutions *pf dhfr* N51I and *pf dhfr* S108N were at fixation in Kenya (i.e. they were nearly 100% prevalent).²⁸ Therefore, we focused our analysis on the remaining three substitutions: *pf dhps* A437G, *pf dhps* K540E and *pf dhfr* C59R. Each PCR reaction included 5 µL of template, 0.3 µM of forward and reverse primers, and 1 × SsoAdvanced Mastermix and 0.2 µM of each of two probes, one corresponding to the mutant allele and the other to the wild-type allele.

Informed consent

Written informed consent was obtained from the parents or guardians of participating children. Approval was granted by Moi University Institutional Research and Ethics Committee in Kenya and Duke University Institutional Review Board in the United States of America. This study was registered with the Pan African Clinical Trials Registry (PACTR20240570172).

Participant and public involvement

Participants were not directly involved in the design of the study. However, suggestions and information provided by the public and community leaders during the formative research phase were critical for designing the seasonal malaria chemoprevention programme.²⁹ The Kenyan health ministry and community leaders were involved in all aspects of the study design, randomization, enrolment and the supervision of study activities.

Results

In total, we enrolled 398 eligible children from 389 households in the study: 198 in the intervention cohort and 200 in non-intervention cohort. Nine households had more than one participating child. The two cohorts were similar at baseline (Table 1). Overall, the children's mean age was 28.9 months, 49% were female and only 50% had a bednet for their sleeping

space. On the day of enrolment, 17% (68/389) reported symptoms and were offered a malaria rapid diagnostic test. Of the 68, 13 (19%) tested positive. Parasite prevalence was measured using a PCR test in all children at enrolment and was found to vary substantially between villages (Fig. 2). Overall, the prevalence was 20% (95% confidence interval, CI: 16–24); it was lower in the non-intervention cohort than the intervention cohort, at 16% versus 23%, respectively ($P = 0.077$).

All 198 children from the intervention area were eligible for seasonal malaria chemoprevention and 143 (72%) received the full five cycles. Of the 55 (28%) who did not receive all five cycles, two (1%) had no chemoprevention at all and 39 (20%) received between one and four cycles. In addition, 14 (7%) children could not be located at the end of the study and their chemoprevention coverage could not be determined fully; however, according to weekly visit records, at least 10 had one or more cycles.

Efficacy of seasonal malaria chemoprevention

We recorded malaria episodes from the last day of the first cycle of seasonal malaria chemoprevention administration until 28 days after the last cycle (i.e. from 18 June 2024 to 7 November 2024). Twenty-two children (14 in the intervention cohort and eight in the control cohort) were lost to follow-up and could not be contacted at the end of the study. In addition, 27 children left the study area during the observation period and missed at least two weekly household visits, but 22 of the 27 returned before the final visit. In total, there were 7585 child–weeks of observation: 3779 in the intervention cohort and 3806 in the control cohort. Between the end of the first chemoprevention cycle and 28 days after the last cycle, 566 febrile events were documented, of which 207 were due to malaria: 58 in the intervention cohort and 149 in the control cohort. These figures correspond to a crude incidence of 87.5 malaria episodes per 100 person–years at risk in the intervention cohort and 202.7 per 100 person–years at risk in the control cohort. Overall, 80% (159/198) of children in the intervention cohort remained malaria-free throughout the study period compared to only 50% (99/200) in the control cohort. After adjusting for the children’s age and bednet use and the cluster-level malaria prevalence at baseline, the incidence rate ratio of malaria episodes in the intervention group compared with the non-intervention group was 0.29 (95% CI: 0.13–0.67). The incidence rate ratio of all fevers in the intervention group compared with the non-intervention group was 0.47 (95% CI: 0.31–0.72), which indicates that a high proportion of fevers was due to malaria. Fig. 3 shows the number of malaria cases per week in the intervention and non-intervention cohorts over the study period.

Malaria episodes were more common in children who had fewer than five cycles of seasonal malaria chemoprevention than in those who had five cycles; 41 of 58 (71%) malaria episodes observed in the intervention cohort occurred in children with incomplete chemoprevention. Moreover, of the 11 children in the intervention cohort who experienced more than one malaria episode during the study, all but one received fewer than five chemoprevention cycles.

Parasite resistance

Of the 351 dried blood spot samples collected, 156 contained *P. falciparum*: 55 of 138 (40%) samples from the intervention cohort and 101 of 213 (47%) samples from the control cohort. At least one of the three genomic positions of interest (i.e. *pfdhfr* 59, *pfdhps* 437 or *pfdhps* 540) was amplified in 90 infections and all three positions were amplified in 68. At least one mutation associated with sulfadoxine–pyrimethamine resistance was present in 54% (37/68) of infections for which all three markers of resistance were amplified. The majority of infections contained at least one wild-type allele involving *pfdhfr* 59, *pfdhps* 437 or *pfdhps* 540. More infections in the intervention cohort than the non-intervention cohort had mixed alleles (i.e. both mutant and wild-type alleles; Table 2), which indicates that multigenomic infections were more common in the intervention cohort. Although the prevalence of the *pfdhps* A437G mutation was significantly higher in the intervention cohort than the non-intervention cohort (*P*-value: 0.030; Table 2), the distribution of mutations of interest was not significantly different between the cohorts (*P*-value: 0.063; Table 3). Finally, the odds of harbouring an allele with the *pfdhps* K540E or *pfdhps* A437G mutation increased significantly with each additional seasonal malaria chemoprevention cycle received (Fig. 4).

Discussion

Seasonal malaria chemoprevention is highly cost-effective for reducing morbidity and mortality from malaria among children. However, experience with the strategy in eastern and southern Africa is limited. In our study, seasonal malaria chemoprevention was successfully deployed in a unique community of pastoralists in northern Kenya and was associated with a significantly lower incidence of malaria episodes in the intervention cohort compared with the non-intervention cohort over the 5 months of the programme. The degree of protection observed in Turkana was lower than that reported in a study from neighbouring Uganda but was generally in agreement with the findings of randomized studies in West Africa and estimates from routine seasonal malaria chemoprevention.^{6,30–32} Nearly three quarters of

malaria episodes in our intervention cohort occurred among children who received fewer than five cycles of chemoprevention, which suggests that the somewhat lower level of protection we observed was attributable to imperfect adherence to treatment. Although children in our study were in regular contact with community health promoters, less than three quarters were confirmed to have received all five cycles.

The remoteness and mobility of the study population were expected to present a challenge for attaining full coverage and indeed more than a 10th of children missed appointments with the study team due to household movement. This proportion is higher than we recorded previously in cross-sectional studies and probably contributed to the suboptimal uptake of seasonal malaria chemoprevention.³³

Parasite populations in East Africa have substantially higher levels, and a higher prevalence, of antifolate resistance than those in West Africa,⁹ which raises concerns about the efficacy of sulfadoxine–pyrimethamine and amodiaquine for seasonal malaria chemoprevention. Although sulfadoxine–pyrimethamine has remained effective for protecting pregnant women,^{7,11,12} it is possible that pre-existing immunity in the mother may play a role in boosting the drugs' effects.³⁴ Consequently, doubts linger about the effectiveness of sulfadoxine–pyrimethamine and amodiaquine for preventing malaria in young, non-immune children exposed to drug-resistant parasites. Nevertheless, several studies, including ours, confirm the high apparent efficacy of this combination in places where drug-resistant parasites predominate.^{13,35–37}

To better understand the relationship between seasonal malaria chemoprevention and parasite resistance, previous studies have compared the prevalence of resistance alleles in *P. falciparum* genes before and after chemoprevention to determine whether the population prevalence of specific alleles may have increased.^{6,38,39} In our study, we focused on antifolate resistance alleles in clinical breakthrough infections that occurred during seasonal malaria chemoprevention to understand the relationship between the selection of sulfadoxine–pyrimethamine resistance genes in parasites and the effectiveness of malaria prevention. We found that the prevalence of the *pf dhps* A437G mutation was significantly higher in incident *P. falciparum* infections among children receiving seasonal malaria chemoprevention than among infections in the comparison cohort. Moreover, the odds of harbouring mutant *pf dhps* 437 and *pf dhps* 540 increased with each chemoprevention cycle. A study in Burkina Faso demonstrated selection for two drug-resistance *dhfr* alleles (i.e. *dhfr* 59R and *dhfr* 108N) in prevalent infections during seasonal malaria chemoprevention.⁴⁰ Although it is not known

whether a small number of breakthrough infections makes a substantial contribution to the spread of sulfadoxine–pyrimethamine resistance, the observation that resistant parasites are more common in breakthrough infections is important because they may increase the risk of disease.

The relationship between scaling up seasonal malaria chemoprevention with sulfadoxine–pyrimethamine and amodiaquine and changes in the prevalence of sulfadoxine–pyrimethamine resistant parasites has been explored in countries where seasonal malaria chemoprevention is routinely implemented at scale. Typically, these studies measure changes in resistance alleles following chemoprevention using repeated, cross-sectional surveys of asymptomatic children or adults.^{6,38,39} Studies lasting 2 to 5 years have not found changes in antifolate resistance in parasite populations,^{6,38} but longer-term studies in Africa reported that antifolate resistance continued to expand over time.³⁹ Although the relationship with seasonal malaria chemoprevention cannot be confirmed, it is the only substantial source of selective pressure from sulfadoxine–pyrimethamine. In East Africa, one study from Uganda reported no difference in the prevalence of antifolate resistance mutations in children within and outside areas where seasonal malaria chemoprevention was implemented.¹³ However, the baseline prevalence of resistance was very high, which left little room for an increase. A major weakness of these ecological studies is the absence of information on the use of seasonal malaria chemoprevention at the individual level and of comparisons between individuals who are and are not eligible for seasonal malaria chemoprevention.

Our study has limitations that should be considered when weighing the evidence. This was not a randomized study. Instead, we selected comparison areas from which to draw the non-intervention villages to maximize their similarity to the intervention area at baseline, reduce confounding and, thereby, improve our inferences about the effect of the intervention. As children who had been treated with antimalarials in the previous two weeks were excluded from the next round of seasonal malaria chemoprevention, it is possible our weekly active monitoring of morbidity may have resulted in fewer children receiving chemoprevention than if less-sensitive passive case detection had been used. Moreover, the increased sensitivity of active case detection may have also led to malaria episodes being registered in children who might not have sought care at a health facility. However, both study cohorts would have been subject to this higher sensitivity and the estimated incidence ratios should not have been affected by bias. As we were able to characterize the three *P. falciparum* genomic positions of interest in less than half of all infections, our comparisons are imprecise, although the

differences we found were significant. We did not evaluate amodiaquine resistance in infected children but the level of resistance was expected to be low in the region.⁴¹ Finally, it remains unclear whether the higher prevalence of sulfadoxine–pyrimethamine-resistant infections in children receiving seasonal malaria chemoprevention contributes to the broader spread of resistance at the population level. Even if resistant infections are transmitted by these children, the reduction in the overall number infected may offset this potential risk.

In conclusion, we found that the protection against malaria illness offered by seasonal malaria chemoprevention with sulfadoxine–pyrimethamine and amodiaquine was high despite the marked prevalence of parasites with mutations in *dhfr* and *dhps* genes linked to sulfadoxine–pyrimethamine resistance. Consequently, expanding seasonal malaria chemoprevention to other regions that experience highly seasonal transmission would be worthwhile. However, given evidence that breakthrough infections by quintuple mutant parasites occur, routine monitoring of breakthrough infections in recipients of seasonal malaria chemoprevention should be established at health facilities to increase understanding of the contribution of resistance to morbidity. Moreover, information about local levels of resistance is important for predicting the parasite's susceptibility to, and the overall efficacy of, chemoprevention.

Acknowledgements

We thank all participating families and community health promoters, the Turkana County Health Team, the enrolment team (Patrick Ejore, Zubeda Ewoi, Chuchu Gregory, Joseph Lobe, Lilian Lokitoe, Emmanuel Lopeto, Kaman Lowoi, Purity Musai, Joyce Nachipon and Jeremiah Nokorot) and Lucy Abel, Shonde Akinola, George Ambani, Tabitha Chepkwony, Rebecca Lokwang, Caroline Ngina, Emily Robie and Conde Mohamed Saran.

Funding:

This study was funded by a grant from PMI Insights, which is funded by the US President's Malaria Initiative, to Moi University.

Competing interests:

None declared.

References

1. Chotsiri P, White NJ, Tarning J. Pharmacokinetic considerations in seasonal malaria chemoprevention. *Trends Parasitol.* 2022 Aug;38(8):673–82. <https://doi.org/10.1016/j.pt.2022.05.003> PMID:35688778
2. Mariga ST, Gil JP, Wernsdorfer WH, Björkman A. Pharmacodynamic interactions of amodiaquine and its major metabolite desethylamodiaquine with artemisinin, quinine and atovaquone in *Plasmodium falciparum* in vitro. *Acta*

Trop. 2005 Mar;93(3):221–31.

<https://doi.org/10.1016/j.actatropica.2005.01.007> PMID:15725382

3. Cairns M, Ceesay SJ, Sagara I, Zongo I, Kessely H, Gamougam K, et al. Effectiveness of seasonal malaria chemoprevention (SMC) treatments when SMC is implemented at scale: case–control studies in 5 countries. PLoS Med. 2021 Sep 8;18(9):e1003727. <https://doi.org/10.1371/journal.pmed.1003727> PMID:34495978
4. Cissé B, Ba EH, Sokhna C, NDiaye JL, Gomis JF, Dial Y, et al. Effectiveness of seasonal malaria chemoprevention in children under ten years of age in Senegal: a stepped-wedge cluster-randomised trial. PLoS Med. 2016 Nov 22;13(11):e1002175. <https://doi.org/10.1371/journal.pmed.1002175> PMID:27875528
5. Druetz T, Corneau-Tremblay N, Millogo T, Kouanda S, Ly A, Bicaba A, et al. Impact evaluation of seasonal malaria chemoprevention under routine program implementation: a quasi-experimental study in Burkina Faso. Am J Trop Med Hyg. 2018 Feb;98(2):524–33. <https://doi.org/10.4269/ajtmh.17-0599> PMID:29260654
6. Baba E, Hamade P, Kivumbi H, Marasciulo M, Maxwell K, Moroso D, et al.; ACCESS-SMC Partnership. Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study. Lancet. 2020 Dec 5;396(10265):1829–40. [https://doi.org/10.1016/S0140-6736\(20\)32227-3](https://doi.org/10.1016/S0140-6736(20)32227-3) PMID:33278936
7. Updated WHO recommendations for malaria chemoprevention among children and pregnant women. Geneva: World Health Organization; 2022. Available from: <https://www.who.int/news/item/03-06-2022-Updated-WHO-recommendations-for-malaria-chemoprevention-among-children-and-pregnant-women> [cited 2025 Jun 17].
8. Okell LC, Griffin JT, Roper C. Mapping sulphadoxine–pyrimethamine-resistant *Plasmodium falciparum* malaria in infected humans and in parasite populations in Africa. Sci Rep. 2017 Aug 7;7(1):7389. <https://doi.org/10.1038/s41598-017-06708-9> PMID:28785011
9. Flegg JA, Humphreys GS, Montanez B, Strickland T, Jacome-Meza ZJ, Barnes KI, et al. Spatiotemporal spread of *Plasmodium falciparum* mutations for resistance to sulfadoxine-pyrimethamine across Africa, 1990–2020. PLOS Comput Biol. 2022 Aug 11;18(8):e1010317. <https://doi.org/10.1371/journal.pcbi.1010317> PMID:35951528
10. Pacheco MA, Schneider KA, Cheng Q, Munde EO, Ndege C, Onyango C, et al. Changes in the frequencies of *Plasmodium falciparum* dhps and dhfr drug-resistant mutations in children from Western Kenya from 2005 to 2018: the rise of *Pfdhps* S436H. Malar J. 2020 Oct 22;19(1):378. <https://doi.org/10.1186/s12936-020-03454-8> PMID:33092587
11. Desai M, Gutman J, Taylor SM, Wiegand RE, Khairallah C, Kayentao K, et al. Impact of sulfadoxine–pyrimethamine resistance on effectiveness of intermittent preventive therapy for malaria in pregnancy at clearing infections and preventing low birth weight. Clin Infect Dis. 2016 Feb 1;62(3):323–33. <https://doi.org/10.1093/cid/civ881> PMID:26486699

12. Roh ME, Kuile FOT, Rerolle F, Glymour MM, Shiboski S, Gosling R, et al. Overall, anti-malarial, and non-malarial effect of intermittent preventive treatment during pregnancy with sulfadoxine–pyrimethamine on birthweight: a mediation analysis. *Lancet Glob Health*. 2020 Jul;8(7):e942–53. [https://doi.org/10.1016/S2214-109X\(20\)30119-4](https://doi.org/10.1016/S2214-109X(20)30119-4) PMID:32562650
13. Nuwa A, Baker K, Kajubi R, Nnaji CA, Theiss-Nyland K, Odongo M, et al. Effectiveness of sulfadoxine–pyrimethamine plus amodiaquine and dihydroartemisinin–piperaquine for seasonal malaria chemoprevention in Uganda: a three-arm, open-label, non-inferiority and superiority, cluster-randomised, controlled trial. *Lancet Infect Dis*. 2025 Jul;25(7):726–36. [https://doi.org/10.1016/S1473-3099\(24\)00746-1](https://doi.org/10.1016/S1473-3099(24)00746-1) PMID:39826559
14. Griffith EF, Kipkemai JR, Nakadio EL, Smith LJ, Amuguni JH. One Health in Turkana County, Kenya: applications and lessons learned. *One Health Cases*. 2023 Jul 6;ohcs20230022. <https://doi.org/10.1079/onehealthcases.2023.0022>
15. 2019 Kenya population and housing census. Volume III: distribution of population by age, sex and administrative units. Nairobi: Kenya National Bureau of Statistics; 2019. Available from: <https://www.knbs.or.ke/wp-content/uploads/2023/09/2019-Kenya-population-and-Housing-Census-Volume-3-Distribution-of-Population-by-Age-and-Sex.pdf> [cited 2025 Jul 23].
16. Mulambalah CS. An evolving malaria epidemic in Kenya: a regional alert. *CHRISMED J Health Res*. 2018 Jan;5(2):162. https://doi.org/10.4103/cjhr.cjhr_104_17
17. MSF responds to malaria outbreak in Turkana. Geneva: Médecins Sans Frontières; 2019 Oct 5. Available from: <https://msf.or.ke/news-and-resources/latest-news/msf-responds-malaria-outbreak-turkana-kenya> [cited 2025 Jun 17].
18. Wickham H, Averick M, Bryan J, Chang W, McGowan LD, François R, et al. Welcome to the Tidyverse. *J Open Source Softw*. 2019 Nov 21;4(43):1686. <https://doi.org/10.21105/joss.01686>
19. Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. *J Stat Softw*. 2015 Oct 7;67(1):1–48. <https://doi.org/10.18637/jss.v067.i01>
20. Therneau TM, Thomas L, Atkinson E, Crowson C. survival: survival analysis. CRAN R Project; 2024. Available from: <https://cran.r-project.org/web/packages/survival/index.html> [cited 2025 Jun 15].
21. Kassambara A, Kosinski M, Biecek P, Fabian S. survminer: drawing survival curves using “ggplot2”. CRAN R Project; 2016. Available from: <https://cran.r-project.org/web/packages/survminer/> [cited 2025 Jun 15].
22. Robinson D, Hayes A, Couch S, Hvitfeldt E, Patil I, Chiu D, et al. broom: convert statistical objects into tidy tibbles. Vienna: CRAN R Project; 2025. Available from: <https://cran.r-project.org/web/packages/broom/index.html> [cited 2025 Jun 15].
23. Zhu H, Travison T, Tsai T, Beasley W, Xie Y, Yu GC, et al. kableExtra: construct complex table with “kable” and pipe syntax. Vienna: CRAN R Project; 2024.

Available from: <https://cran.r-project.org/web/packages/kableExtra/index.html>
[cited 2025 Jun 15].

24. Snounou G, Singh B. Nested PCR analysis of *Plasmodium* parasites. *Methods Mol Med*. 2002;72:189–203. <https://doi.org/10.1385/1-59259-271-6:189> PMID:12125116
25. Perandin F, Manca N, Calderaro A, Piccolo G, Galati L, Ricci L, et al. Development of a real-time PCR assay for detection of *Plasmodium falciparum*, *Plasmodium vivax*, and *Plasmodium ovale* for routine clinical diagnosis. *J Clin Microbiol*. 2004 Mar;42(3):1214–9. <https://doi.org/10.1128/JCM.42.3.1214-1219.2004> PMID:15004078
26. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE. Pyrimethamine and proguanil resistance-conferring mutations in *Plasmodium falciparum* dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. *Am J Trop Med Hyg*. 1995 Jun;52(6):565–8. <https://doi.org/10.4269/ajtmh.1995.52.565> PMID:7611566
27. Alker AP, Mwapasa V, Meshnick SR. Rapid real-time PCR genotyping of mutations associated with sulfadoxine–pyrimethamine resistance in *Plasmodium falciparum*. *Antimicrob Agents Chemother*. 2004 Aug;48(8):2924–9. <https://doi.org/10.1128/AAC.48.8.2924-2929.2004> PMID:15273102
28. White NFD, Whitton G, Wasakul V, Amenga-Etego L, Dara A, Andrianaranjaka V, et al. Disparate co-evolution and prevalence of sulfadoxine and pyrimethamine resistance alleles and haplotypes at *dhfr* and *dhps* genes across Africa. *Sci Rep*. 2025 Apr 17;15(1):13222. <https://doi.org/10.1038/s41598-025-98035-7> PMID:40247054
29. Kostandova N, Kafu C, Chepkwony TJ, Ambani G, Abel L, Rotich B, et al. A baseline mixed-methods study to inform seasonal malaria chemoprevention delivery in a semi-nomadic population in Turkana, Kenya. *Am J Trop Med Hyg*. 2025 Dec 30;114(3):466–80. <https://doi.org/10.4269/ajtmh.24-0832> PMID:41666451
30. Thwing J, Williamson J, Cavros I, Gutman JR. Systematic review and meta-analysis of seasonal malaria chemoprevention. *Am J Trop Med Hyg*. 2023 Dec 11;110(1):20–31. <https://doi.org/10.4269/ajtmh.23-0481> PMID:38081050
31. Bisanzio D, Keita MS, Camara A, Guilavogui T, Diallo T, Barry H, et al. Malaria trends in districts that were targeted and not-targeted for seasonal malaria chemoprevention in children under 5 years of age in Guinea, 2014–2021. *BMJ Glob Health*. 2024 Feb 26;9(2):e013898. <https://doi.org/10.1136/bmjgh-2023-013898> PMID:38413098
32. Kirakoya-Samadoulougou F, De Brouwere V, Fokam AF, Ouédraogo M, Yé Y. Assessing the effect of seasonal malaria chemoprevention on malaria burden among children under 5 years in Burkina Faso. *Malar J*. 2022 May 6;21(1):143. <https://doi.org/10.1186/s12936-022-04172-z> PMID:35524310
33. Meredith HR, Wesolowski A, Menya D, Esimit D, Lokoel G, Kipkoech J, et al. Epidemiology of *Plasmodium falciparum* infections in a semi-arid rural African setting: evidence from reactive case detection in northwestern Kenya. *Am J*

Trop Med Hyg. 2021 Aug 2;105(4):1076–84. <https://doi.org/10.4269/ajtmh.21-0256> PMID:34339387

34. Staedke SG, Sendagire H, Lamola S, Kamya MR, Dorsey G, Rosenthal PJ. Relationship between age, molecular markers, and response to sulphadoxine–pyrimethamine treatment in Kampala, Uganda. *Trop Med Int Health*. 2004 May;9(5):624–9. <https://doi.org/10.1111/j.1365-3156.2004.01239.x> PMID:15117308
35. Khan J, Suau Sans M, Okot F, Rom Ayuiel A, Magoola J, Rassi C, et al. A quasi-experimental study to estimate effectiveness of seasonal malaria chemoprevention in Aweil South County in Northern Bahr El Ghazal, South Sudan. *Malar J*. 2024 Jan 24;23(1):33. <https://doi.org/10.1186/s12936-024-04853-x> PMID:38267985
36. Molina-de la Fuente I, Sagrado Benito MJ, Lasry E, Ousley J, García L, González V, et al. Seasonal malaria chemoprevention in a context of high presumed sulfadoxine–pyrimethamine resistance: malaria morbidity and molecular drug resistance profiles in South Sudan. *Malar J*. 2023 Nov 10;22(1):345. <https://doi.org/10.1186/s12936-023-04740-x> PMID:37950227
37. Baker K, Pulido Tarquino IA, Aide P, Bonnington C, Rassi C, Richardson S, et al. Phase one of a hybrid effectiveness–implementation study to assess the feasibility, acceptability and effectiveness of implementing seasonal malaria chemoprevention in Nampula Province, Mozambique. *Malar J*. 2025 Feb 21;24(1):56. <https://doi.org/10.1186/s12936-024-05229-x> PMID:39985013
38. Beshir KB, Muwanguzi J, Nader J, Mansukhani R, Traore A, Gamougam K, et al. Prevalence of *Plasmodium falciparum* haplotypes associated with resistance to sulfadoxine–pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study. *Lancet Infect Dis*. 2023 Mar;23(3):361–70. [https://doi.org/10.1016/S1473-3099\(22\)00593-X](https://doi.org/10.1016/S1473-3099(22)00593-X) PMID:36328000
39. Bohissou FET, Sondo P, Inoue J, Rouamba T, Kaboré B, Nassa GJW, et al. Evolution of *Pf dhps* and *Pf dhfr* mutations before and after adopting seasonal malaria chemoprevention in Nanoro, Burkina Faso. *Sci Rep*. 2024 Oct 16;14(1):24224. <https://doi.org/10.1038/s41598-024-75369-2> PMID:39414909
40. Somé AF, Zongo I, Compaoré YD, Sakandé S, Nosten F, Ouédraogo JB, et al. Selection of drug resistance-mediating *Plasmodium falciparum* genetic polymorphisms by seasonal malaria chemoprevention in Burkina Faso. *Antimicrob Agents Chemother*. 2014 Jul;58(7):3660–5. <https://doi.org/10.1128/AAC.02406-14> PMID:24733476
41. Lucchi NW, Komino F, Okoth SA, Goldman I, Onyona P, Wiegand RE, et al. In vitro and molecular surveillance for antimalarial drug resistance in *Plasmodium falciparum* parasites in western Kenya reveals sustained artemisinin sensitivity and increased chloroquine sensitivity. *Antimicrob Agents Chemother*. 2015 Dec;59(12):7540–7. <https://doi.org/10.1128/AAC.01894-15> PMID:26392510

Table 1. Participants' characteristics at baseline, study of seasonal malaria chemoprevention and parasite drug resistance, Kenya, 2024

Child's characteristic	No. (%) of children ^a			<i>P</i> ^b
	Overall (<i>n</i> = 398)	Intervention (<i>n</i> = 198)	Control (<i>n</i> = 200)	
Age in months, mean (SD)	28.9 (14.3)	28.7 (14.5)	29.1 (14.2)	0.77
Female sex	195 (49)	96 (48)	99 (50)	0.84
Has bednet for sleeping space	198 (50)	106 (54)	92 (46)	0.13
Sleeps outside	88 (22)	40 (20)	48 (24)	0.36
Symptomatic at enrolment	68 (17)	38 (19)	30 (15)	0.22
Symptoms plus positive malaria rapid diagnostic test result	13 (3.3)	9 (4.5)	4 (2.0)	0.59

SD: standard deviation.

^a All values represent absolute numbers and percentages unless otherwise stated.

^b We calculated *P*-values using the χ^2 test except for the age comparison, which used a two-sample *t*-test.

Note: Turkana Central was the intervention subcounty, where children received seasonal malaria chemoprevention, and Turkana North subcounty was the control area.

Table 2. Prevalence of selected *Plasmodium falciparum* alleles in blood spot samples, by subcounty, study of seasonal malaria chemoprevention and parasite drug resistance, Kenya, 2024

Genomic position and allele type	No. (%) blood spot samples from children with <i>P. falciparum</i> infections ^a			
	Overall	Intervention	Control	<i>P</i> ^b
<i>pfdhfr</i> 59				
Allele type				0.500
All	86 (100.0)	27 (100.0)	59 (100.0)	NA
Mixed	11 (12.8)	5 (18.5)	6 (10.2)	NA
Mutant	27 (31.4)	7 (25.9)	20 (33.9)	NA
Wild-type	48 (55.8)	15 (55.6)	33 (55.9)	NA
<i>pfdhps</i> 540				
Allele type				0.113
All	70 (100.0)	23 (100.0)	47 (100.0)	NA
Mixed	6 (8.6)	4 (17.4)	2 (4.3)	NA
Mutant	12 (17.1)	5 (21.7)	7 (14.9)	NA
Wild	52 (74.3)	14 (60.9)	38 (80.9)	NA
<i>pfdhps</i> 437				
Allele type				0.030
All	87 (100.0)	26 (100.0)	61 (100.0)	NA
Mixed	19 (21.8)	7 (26.9)	12 (19.7)	NA
Mutant	12 (13.8)	7 (26.9)	5 (8.2)	NA
Wild	56 (64.4)	12 (46.2)	44 (72.1)	NA

NA: not applicable; *P. falciparum*: *Plasmodium falciparum*.

^a Mutations in *Plasmodium falciparum* *pfdhfr* and *pfdhps* genes that confer resistance to sulfadoxine–pyrimethamine were detected in dried blood spot samples from children using a polymerase chain reaction (PCR) allelic discrimination assay.

^b We calculated *P*-values using the χ^2 test for differences in the distribution of the three allele types (i.e. mixed, mutant and wild type) between infections in intervention and control areas.

Note: Turkana Central was the intervention subcounty, where children received seasonal malaria chemoprevention, and Turkana North subcounty was the control area.

Table 3. Prevalence of sulfadoxine–pyrimethamine-resistance mutations, by subcounty, study of seasonal malaria chemoprevention and parasite drug resistance, northern Kenya, 2024

Resistance mutations detected and level of sulfadoxine–pyrimethamine resistance ^a	No. (%) blood spot samples from children with <i>P. falciparum</i> infections			<i>P</i> ^c
	Overall (n = 74) ^b	Intervention (n = 24)	Control (n = 50)	
Mutations^d				0.063
<i>pf dhps</i> A437G alone	2 (2.7)	2 (8.3)	0 (0.0)	NA
<i>pf dhps</i> A437G and K540E	6 (8.1)	3 (12.5)	3 (6.0)	NA
<i>pf dhps</i> A437G and <i>pf dhfr</i> C59R	3 (4.1)	1 (4.2)	2 (4.0)	NA
<i>pf dhps</i> A437G and K540E and <i>pf dhfr</i> C59R	11 (14.9)	6 (25.0)	5 (10.0)	NA
<i>pf dhfr</i> C59R alone	15 (20.3)	2 (8.3)	13 (26.0)	NA
Wild type ^e	37 (50.0)	10 (41.7)	27 (54.0)	NA
Resistance level^f				0.119
0	37 (50.0)	10 (41.7)	27 (54.0)	NA
1	20 (27.0)	5 (20.8)	15 (30.0)	NA
2	17 (23.0)	9 (37.5)	8 (16.0)	NA

NA: not applicable; PCR: polymerase chain reaction; *P. falciparum*: *Plasmodium falciparum*.

^a *P. falciparum* resistance mutations were detected in dried blood spot samples from children using a PCR allelic discrimination assay.

^b Samples were obtained from 68 infections in children in whom all three genomic positions of interest (i.e. *pf dhfr* 59, *pf dhps* 437 and *pf dhps* 540) were amplified on PCR analysis plus six infections in children in whom *pf dhps* 540 was not amplified. In these six infections, wild-type *pf dhfr* 59 and *pf dhps* 437 were detected and it was assumed that wild-type *pf dhps* 540 was present because it is very rare for *pf dhps* 540 mutations to occur in the absence of mutations at the other two positions.

^c We calculated *P*-values using the χ^2 test for differences in the distribution of the six combinations of mutations between infections in intervention and control areas.


^d Five dominant mutations in *pf dhfr* and *pf dhps* genes confer resistance to sulfadoxine–pyrimethamine. As previous studies in Kenya found that the prevalence of two of these mutations (i.e. *pf dhfr* S108N and *pf dhfr* N51I) was 100%, which we confirmed in a pilot study involving 10 samples, we assumed all parasites in our study area had these two mutations.

^e Wild type indicates that wild-type *pf dhfr* 59, *pf dhps* 540 and *pf dhps* 437 were all detected. For six samples, wild-type *pf dhfr* 59 and *pf dhps* 437 were detected but wild-type *pf dhps* 540 was not, they were also assumed to be wild type.

^f The level of sulfadoxine–pyrimethamine resistance among parasites was attributed as follows: (i) 0 for wild-type *pf dhfr* 59, *pf dhps* 540 and *pf dhps* 437; (ii) 1 (i.e. low) for mutations at *pf dhps* 437 alone, *pf dhfr* 59 alone, and *pf dhps* 437 plus *pf dhfr* 59; and (iii) 2 (i.e. high) for mutations at *pf dhps* K540E, with other mutations or alone.


Note: Turkana Central was the intervention subcounty, where children received seasonal malaria chemoprevention, and Turkana North subcounty was the control area.

Fig. 1. Study villages, Turkana County, study of seasonal malaria chemoprevention and parasite drug resistance, Kenya, 2024



Notes: children in villages marked by blue dots in Turkana Central subcounty received seasonal malaria chemoprevention. Children in villages marked by red dots in Turkana North subcounty served as a non-intervention comparison population. There were 10 villages in each of Turkana Central and Turkana North subcounties but not all are visible on the map because some dots overlap.


Fig. 2. **Prevalence of *Plasmodium falciparum* infection at study enrolment, by subcounty and village, study of seasonal malaria chemoprevention and parasite drug resistance, Kenya, 2024**



P. falciparum: *Plasmodium falciparum*.


Notes: children in villages in Turkana Central subcounty received seasonal malaria chemoprevention. Children in villages in Turkana North subcounty served as a non-intervention comparison population. The presence of a *Plasmodium falciparum* infection was detected using a polymerase chain reaction (PCR) test.

Fig. 3. **Weekly malaria episodes, by subcounty, study of seasonal malaria chemoprevention and parasite drug resistance, Kenya, 2024**



Notes: Turkana Central was the intervention subcounty, where children received seasonal malaria chemoprevention, and Turkana North subcounty was the control area.

Fig. 4. Odds of *Plasmodium falciparum* in infected children harbouring a *pf dhps* K540E, *pf dhfr* C59R or *pf dhps* A437G mutation in the subsequent seasonal malaria chemoprevention cycle, study of seasonal malaria chemoprevention and parasite drug resistance, Kenya, 2024



CI: confidence interval; OR: odds ratio; *P. falciparum*: *Plasmodium falciparum*.

Notes: in the regression analysis, the number of seasonal malaria chemoprevention cycles was treated as a continuous variable, ranging from 0 to 5. The odds can be interpreted as the relative change in the risk of infection by *Plasmodium falciparum* that harboured the specific mutation between one treatment cycle and the subsequent cycle. The odds ratios were not adjusted for any covariates.